Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2′-O-Methoxyethyl Antisense Oligonucleotide-Reference-Cited by-同舟云学术

Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2′-O-Methoxyethyl Antisense Oligonucleotide

Published:2019-10-01 Issue:5 Volume:29 Page:266-277
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

Pirie Elaine¹,Cauntay Patrick²,Fu Wuxia¹,Ray Shayoni¹,Pan Calvin³,Lusis Aldonis J.³,Hsiao Jill²,Burel Sebastien A.²,Narayanan Padma²,Crooke Rosanne M.¹,Lee Richard G.¹

Affiliation:

1. Cardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.

2. Preclinical Development, Ionis Pharmaceuticals, Carlsbad, California.

3. Department of Human Genetics, University of California, Los Angeles, Los Angeles, California.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Link

https://www.liebertpub.com/doi/pdf/10.1089/nat.2019.0797

Reference53 articles.

1. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial